What Is the Purpose of the Orphan Drug Act?
نویسنده
چکیده
Matthew Herder suggests it may be time to re-examine the purpose of the U.S. Orphan Drug Act.
منابع مشابه
Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs Cataloguing FDA’s Flexibility in Regulating Therapies for Persons with Rare Disorders
One of the key underlying issues facing the development of all drugs, and particularly orphan drugs, is what kind of evidence the Food and Drug Administration (FDA) requires for approval. The Federal Food, Drug, and Cosmetic [FD&C] Act provides that for FDA to grant approval for a new drug, there must be “substantial evidence” of effectiveness derived from “adequate and well-controlled investig...
متن کاملIncreasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act
1. Introduction 2. Economics of the pharmaceutical R&D process 2a. Costs and risks 2b. R&D returns 2c. The critical significance of patents in pharmaceuticals 3. The Orphan Drug Act of 1983 3a. Push and pull incentive programs 3b. Characteristics of the Orphan Drug Act 3c. Orphan drug designation and approvals 3d. Costs of orphan drugs 3e. Revenues from marketed orphan drugs 3f. Health benefits...
متن کاملUnderstanding Personal Practical Knowledge; From what teachers must know to what teachers already know
The purpose of this study is understanding the Personal Practical Knowledge (PPK) of teachers which has been done through qualitative method. Understanding PPK helps us to understand why teachers act in a specific way. In this regards, reflecting on their personal and professional narratives also help to improve their practice. This study was conducted along with 13 teachers in a non-profit pri...
متن کاملPressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act
BACKGROUND Lysosomal storage disorders are a heterogeneous group of approximately 50 monogenically inherited orphan conditions. A defect leads to the storage of complex molecules in the lysosome, and patients develop a complex multisystemic phenotype of high morbidity often associated with premature death. More than 30 years ago the Orphan Drug Act of 1983 passed the United States legislation i...
متن کاملCrafting a robust business model for orphan drug development.
As research into drugs targeting rare or ‘‘orphan’’ diseases has stepped up in recent years, so too has the need for a robust business model capable of bringing promising orphan drugs into the marketplace. The earliest step took place in 1983, when President Ronald Reagan signed into law the Orphan Drug Act. More than a quarter-century later, the orphan disease community is looking again to Was...
متن کامل